RIGEL PHARMACEUTICALS 1 RSS Feed | Nachrichten - www.finanzen.net

Rigel Provides Business Update and 2026 Outlook

Mon, 12 Jan 2026 14:05:00 +0100

Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues ...

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Fri, 09 Jan 2026 14:05:00 +0100

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: ...

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

Wed, 07 Jan 2026 14:05:00 +0100

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), ...

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Sun, 07 Dec 2025 15:30:00 +0100

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients
RBC-TI was achieved ...

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Wed, 26 Nov 2025 14:05:00 +0100

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), ...

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Mon, 17 Nov 2025 14:05:00 +0100

Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based ...

Rigel to Present at the Jefferies Global Healthcare Conference in London

Wed, 12 Nov 2025 14:05:00 +0100

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), ...

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Tue, 04 Nov 2025 22:01:00 +0100

Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations ...

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

Mon, 03 Nov 2025 15:05:00 +0100

Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk ...

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Wed, 29 Oct 2025 13:05:00 +0100

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) ...